1
|
Rondeaux J, Groussard D, Renet S, Tardif V, Dumesnil A, Chu A, Di Maria L, Lemarcis T, Valet M, Henry JP, Badji Z, Vézier C, Béziau-Gasnier D, Neele AE, de Winther MPJ, Guerrot D, Brand M, Richard V, Durand E, Brakenhielm E, Fraineau S. Ezh2 emerges as an epigenetic checkpoint regulator during monocyte differentiation limiting cardiac dysfunction post-MI. Nat Commun 2023; 14:4461. [PMID: 37491334 PMCID: PMC10368741 DOI: 10.1038/s41467-023-40186-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Accepted: 07/18/2023] [Indexed: 07/27/2023] Open
Abstract
Epigenetic regulation of histone H3K27 methylation has recently emerged as a key step during alternative immunoregulatory M2-like macrophage polarization; known to impact cardiac repair after Myocardial Infarction (MI). We hypothesized that EZH2, responsible for H3K27 methylation, could act as an epigenetic checkpoint regulator during this process. We demonstrate for the first time an ectopic EZH2, and putative, cytoplasmic inactive localization of the epigenetic enzyme, during monocyte differentiation into M2 macrophages in vitro as well as in immunomodulatory cardiac macrophages in vivo in the post-MI acute inflammatory phase. Moreover, we show that pharmacological EZH2 inhibition, with GSK-343, resolves H3K27 methylation of bivalent gene promoters, thus enhancing their expression to promote human monocyte repair functions. In line with this protective effect, GSK-343 treatment accelerated cardiac inflammatory resolution preventing infarct expansion and subsequent cardiac dysfunction in female mice post-MI in vivo. In conclusion, our study reveals that pharmacological epigenetic modulation of cardiac-infiltrating immune cells may hold promise to limit adverse cardiac remodeling after MI.
Collapse
Affiliation(s)
- Julie Rondeaux
- Univ Rouen Normandie, Inserm EnVI UMR 1096, F-76000, Rouen, France
| | | | - Sylvanie Renet
- Univ Rouen Normandie, Inserm EnVI UMR 1096, F-76000, Rouen, France
| | - Virginie Tardif
- Univ Rouen Normandie, Inserm EnVI UMR 1096, F-76000, Rouen, France
| | - Anaïs Dumesnil
- Univ Rouen Normandie, Inserm EnVI UMR 1096, F-76000, Rouen, France
| | - Alphonse Chu
- Sprott Center for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research Institute, General Hospital, Mailbox 511, 501 Smyth Road, Ottawa, ON K1H8L6, Canada
| | - Léa Di Maria
- Univ Rouen Normandie, Inserm EnVI UMR 1096, F-76000, Rouen, France
| | - Théo Lemarcis
- Univ Rouen Normandie, Inserm EnVI UMR 1096, F-76000, Rouen, France
| | - Manon Valet
- Univ Rouen Normandie, Inserm EnVI UMR 1096, F-76000, Rouen, France
| | - Jean-Paul Henry
- Univ Rouen Normandie, Inserm EnVI UMR 1096, F-76000, Rouen, France
| | - Zina Badji
- CHU Rouen, Department of Cardiology, F-76000, Rouen, France
| | - Claire Vézier
- CHU Rouen, Department of Cardiology, F-76000, Rouen, France
| | | | - Annette E Neele
- Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Menno P J de Winther
- Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Dominique Guerrot
- Univ Rouen Normandie, Inserm EnVI UMR 1096, CHU Rouen, Department of Nephrology, F-76000, Rouen, France
| | - Marjorie Brand
- Sprott Center for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research Institute, General Hospital, Mailbox 511, 501 Smyth Road, Ottawa, ON K1H8L6, Canada
| | - Vincent Richard
- Univ Rouen Normandie, Inserm EnVI UMR 1096, CHU Rouen, Department of Pharmacology, F-76000, Rouen, France
| | - Eric Durand
- Univ Rouen Normandie, Inserm EnVI UMR 1096, CHU Rouen, Department of Cardiology, F-76000, Rouen, France
| | - Ebba Brakenhielm
- Univ Rouen Normandie, Inserm EnVI UMR 1096, F-76000, Rouen, France
| | - Sylvain Fraineau
- Univ Rouen Normandie, Inserm EnVI UMR 1096, F-76000, Rouen, France.
| |
Collapse
|
2
|
Leuillier M, Platel V, Tu L, Feugray G, Thuillet R, Groussard D, Messaoudi H, Ottaviani M, Chelgham M, Nicol L, Mulder P, Humbert M, Richard V, Morisseau C, Brunel V, Duflot T, Guignabert C, Bellien J. Inhibition of Soluble Epoxide Hydrolase Does Not Promote or Aggravate Pulmonary Hypertension in Rats. Cells 2023; 12:cells12040665. [PMID: 36831332 PMCID: PMC9954493 DOI: 10.3390/cells12040665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Revised: 02/15/2023] [Accepted: 02/17/2023] [Indexed: 02/22/2023] Open
Abstract
Inhibitors of soluble epoxide hydrolase (sEH), which catalyzes the hydrolysis of various natural epoxides to their corresponding diols, present an opportunity for developing oral drugs for a range of human cardiovascular and inflammatory diseases, including, among others, diabetes and neuropathic pain. However, some evidence suggests that their administration may precipitate the development of pulmonary hypertension (PH). We thus evaluated the impact of chronic oral administration of the sEH inhibitor TPPU (N-[1-(1-Oxopropyl)-4-piperidinyl]-N'-[4-(trifluoromethoxy)phenyl]-urea) on hemodynamics, pulmonary vascular reactivity, and remodeling, as well as on right ventricular (RV) dimension and function at baseline and in the Sugen (SU5416) + hypoxia (SuHx) rat model of severe PH. Treatment with TPPU started 5 weeks after SU5416 injection for 3 weeks. No differences regarding the increase in pulmonary vascular resistance, remodeling, and inflammation, nor the abolishment of phenylephrine-induced pulmonary artery constriction, were noted in SuHx rats. In addition, TPPU did not modify the development of RV dysfunction, hypertrophy, and fibrosis in SuHx rats. Similarly, none of these parameters were affected by TPPU in normoxic rats. Complementary in vitro data demonstrated that TPPU reduced the proliferation of cultured human pulmonary artery-smooth muscle cells (PA-SMCs). This study demonstrates that inhibition of sEH does not induce nor aggravate the development of PH and RV dysfunction in SuHx rats. In contrast, a potential beneficial effect against pulmonary artery remodeling in humans is suggested.
Collapse
Affiliation(s)
- Matthieu Leuillier
- INSERM EnVI UMR 1096, Health Campus, University of Rouen Normandie, F-76000 Rouen, France
| | - Valentin Platel
- INSERM EnVI UMR 1096, Health Campus, University of Rouen Normandie, F-76000 Rouen, France
| | - Ly Tu
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
- Faculté de Médecine, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, France
| | - Guillaume Feugray
- INSERM EnVI UMR 1096, Health Campus, University of Rouen Normandie, F-76000 Rouen, France
- Department of General Biochemistry, CHU Rouen, F-76000 Rouen, France
| | - Raphaël Thuillet
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
- Faculté de Médecine, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, France
| | - Déborah Groussard
- INSERM EnVI UMR 1096, Health Campus, University of Rouen Normandie, F-76000 Rouen, France
| | - Hind Messaoudi
- INSERM EnVI UMR 1096, Health Campus, University of Rouen Normandie, F-76000 Rouen, France
| | - Mina Ottaviani
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
- Faculté de Médecine, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, France
| | - Mustapha Chelgham
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
- Faculté de Médecine, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, France
| | - Lionel Nicol
- INSERM EnVI UMR 1096, Health Campus, University of Rouen Normandie, F-76000 Rouen, France
| | - Paul Mulder
- INSERM EnVI UMR 1096, Health Campus, University of Rouen Normandie, F-76000 Rouen, France
| | - Marc Humbert
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
- Faculté de Médecine, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, France
| | - Vincent Richard
- INSERM EnVI UMR 1096, Health Campus, University of Rouen Normandie, F-76000 Rouen, France
- Department of Pharmacology, CHU Rouen, F-76000 Rouen, France
| | - Christophe Morisseau
- Department of Entomology and Nematology, UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA
| | - Valéry Brunel
- Department of General Biochemistry, CHU Rouen, F-76000 Rouen, France
| | - Thomas Duflot
- INSERM EnVI UMR 1096, Health Campus, University of Rouen Normandie, F-76000 Rouen, France
- Department of Pharmacology, CHU Rouen, F-76000 Rouen, France
| | - Christophe Guignabert
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France
- Faculté de Médecine, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, France
- Correspondence: (C.G.); (J.B.)
| | - Jérémy Bellien
- INSERM EnVI UMR 1096, Health Campus, University of Rouen Normandie, F-76000 Rouen, France
- Department of Pharmacology, CHU Rouen, F-76000 Rouen, France
- Correspondence: (C.G.); (J.B.)
| |
Collapse
|
3
|
Verdier A, Dominique N, Groussard D, Aldanondo A, Bathellier B, Bagur S. Enhanced perceptual task performance without deprivation in mice using medial forebrain bundle stimulation. Cell Rep Methods 2022; 2:100355. [PMID: 36590697 PMCID: PMC9795331 DOI: 10.1016/j.crmeth.2022.100355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 10/04/2022] [Accepted: 11/09/2022] [Indexed: 05/11/2023]
Abstract
Perceptual decision-making tasks are essential to many fields of neuroscience. Current protocols generally reward deprived animals with water. However, balancing animals' deprivation level with their well-being is challenging, and trial number is limited by satiation. Here, we present electrical stimulation of the medial forebrain bundle (MFB) as an alternative that avoids deprivation while yielding stable motivation for thousands of trials. Using licking or lever press as a report, MFB animals learnt auditory discrimination tasks at similar speed to water-deprived mice. Moreover, they more reliably reached higher accuracy in harder tasks, performing up to 4,500 trials per session without loss of motivation. MFB stimulation did not impact the underlying sensory behavior since psychometric parameters and response times are preserved. MFB mice lacked signs of metabolic or behavioral stress compared with water-deprived mice. Overall, MFB stimulation is a highly promising tool for task learning because it enhances task performance while avoiding deprivation.
Collapse
Affiliation(s)
- Antonin Verdier
- Institut de l’Audition, Institut Pasteur, Université de Paris, INSERM, 75012 Paris, France
| | - Noémi Dominique
- Institut Pasteur, Université Paris Cité, DT, Animalerie Centrale, 75724 Paris, France
| | - Déborah Groussard
- Institut Pasteur, Université Paris Cité, DT, Animalerie Centrale, 75724 Paris, France
| | - Anna Aldanondo
- Institut de l’Audition, Institut Pasteur, Université de Paris, INSERM, 75012 Paris, France
| | - Brice Bathellier
- Institut de l’Audition, Institut Pasteur, Université de Paris, INSERM, 75012 Paris, France
| | - Sophie Bagur
- Institut de l’Audition, Institut Pasteur, Université de Paris, INSERM, 75012 Paris, France
| |
Collapse
|
4
|
Guerrot D, Hamzaoui M, Groussard D, Nezam D, Mulder P, Richard V, Bellien J. Endotheilum-specific deficiency of polycystin-1 promotes hypertension and cardiovascular disorders, and impairs arterio-venous fistula maturation. Nephrol Ther 2022. [DOI: 10.1016/j.nephro.2022.07.259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Leuillier M, Duflot T, Ménoret S, Messaoudi H, Djerada Z, Groussard D, Denis RG, Chevalier L, Karoui A, Panthu B, Thiébaut PA, Schmitz-Afonso I, Nobis S, Campart C, Henry T, Sautreuil C, Luquet SH, Beseme O, Féliu C, Peyret H, Nicol L, Henry JP, Renet S, Mulder P, Wan D, Tesson L, Heslan JM, Duché A, Jacques S, Ziegler F, Brunel V, Rautureau GJ, Monteil C, do Rego JL, do Rego JC, Afonso C, Hammock B, Madec AM, Pinet F, Richard V, Anegon I, Guignabert C, Morisseau C, Bellien J. CRISPR/Cas9-mediated inactivation of the phosphatase activity of soluble epoxide hydrolase prevents obesity and cardiac ischemic injury. J Adv Res 2022; 43:163-174. [PMID: 36585106 PMCID: PMC9811321 DOI: 10.1016/j.jare.2022.03.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 02/28/2022] [Accepted: 03/02/2022] [Indexed: 01/07/2023] Open
Abstract
INTRODUCTION Although the physiological role of the C-terminal hydrolase domain of the soluble epoxide hydrolase (sEH-H) is well investigated, the function of its N-terminal phosphatase activity (sEH-P) remains unknown. OBJECTIVES This study aimed to assess in vivo the physiological role of sEH-P. METHODS CRISPR/Cas9 was used to generate a novel knock-in (KI) rat line lacking the sEH-P activity. RESULTS The sEH-P KI rats has a decreased metabolism of lysophosphatidic acids to monoacyglycerols. KI rats grew almost normally but with less weight and fat mass gain while insulin sensitivity was increased compared to wild-type rats. This lean phenotype was more marked in males than in female KI rats and mainly due to decreased food consumption and enhanced energy expenditure. In fact, sEH-P KI rats had an increased lipolysis allowing to supply fatty acids as fuel to potentiate brown adipose thermogenesis under resting condition and upon cold exposure. The potentiation of thermogenesis was abolished when blocking PPARγ, a nuclear receptor activated by intracellular lysophosphatidic acids, but also when inhibiting simultaneously sEH-H, showing a functional interaction between the two domains. Furthermore, sEH-P KI rats fed a high-fat diet did not gain as much weight as the wild-type rats, did not have increased fat mass and did not develop insulin resistance or hepatic steatosis. In addition, sEH-P KI rats exhibited enhanced basal cardiac mitochondrial activity associated with an enhanced left ventricular contractility and were protected against cardiac ischemia-reperfusion injury. CONCLUSION Our study reveals that sEH-P is a key player in energy and fat metabolism and contributes together with sEH-H to the regulation of cardiometabolic homeostasis. The development of pharmacological inhibitors of sEH-P appears of crucial importance to evaluate the interest of this promising therapeutic strategy in the management of obesity and cardiac ischemic complications.
Collapse
Affiliation(s)
- Matthieu Leuillier
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Thomas Duflot
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France,Department of Pharmacology, Rouen University Hospital, F-76000 Rouen, France,Laboratory of Pharmacokinetics, Toxicology and Pharmacogenetics, Rouen University Hospital, F-76000 Rouen, France
| | - Séverine Ménoret
- Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000 Nantes, France,Nantes Université, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France,Transgenesis Rat ImmunoPhenomic Platform, F-44000 Nantes, France
| | - Hind Messaoudi
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Zoubir Djerada
- Department of Pharmacology, EA 3801, SFR CAP-santé, Reims University Hospital, F-51095 Reims Cedex, France
| | - Déborah Groussard
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Raphaël G.P. Denis
- Unité de Biologie Fonctionnelle et Adaptative, Centre National la Recherche scientifique, Université de Paris, BFA, UMR 8251, CNRS, F-75013 Paris, France
| | - Laurence Chevalier
- Normandie University, Unirouen, INSA Rouen, CNRS, Groupe de Physique des Matériaux-UMR6634, F-76000 Rouen, France
| | - Ahmed Karoui
- Normandie Univ, UNIROUEN, UNICAEN, ABTE, F-76000 Rouen, France
| | - Baptiste Panthu
- CarMeN Laboratory, INSERM, INRA, INSA, Université Claude Bernard Lyon 1, F-69600 Oullins, France
| | | | - Isabelle Schmitz-Afonso
- Normandie Univ, COBRA, UMR 6014 and FR 3038, Université de Rouen, INSA de Rouen, CNRS, IRCOF, F-76821, Mont-Saint-Aignan, Cedex, France
| | - Séverine Nobis
- Animal Behavioral Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, F-76183 Rouen, France
| | - Cynthia Campart
- Animal Behavioral Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, F-76183 Rouen, France
| | - Tiphaine Henry
- Animal Behavioral Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, F-76183 Rouen, France
| | - Camille Sautreuil
- Normandie Univ, UNIROUEN, INSERM U1245 and Rouen University Hospital, Department of Neonatal Paediatrics and Intensive Care, F-76000, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
| | - Serge H. Luquet
- Unité de Biologie Fonctionnelle et Adaptative, Centre National la Recherche scientifique, Université de Paris, BFA, UMR 8251, CNRS, F-75013 Paris, France
| | - Olivia Beseme
- Univ. Lille, CHU Lille, Inserm, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000 Lille, France
| | - Catherine Féliu
- Department of Pharmacology, EA 3801, SFR CAP-santé, Reims University Hospital, F-51095 Reims Cedex, France
| | - Hélène Peyret
- Department of Pharmacology, EA 3801, SFR CAP-santé, Reims University Hospital, F-51095 Reims Cedex, France
| | - Lionel Nicol
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Jean-Paul Henry
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Sylvanie Renet
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Paul Mulder
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Debin Wan
- Department of Entomology and Nematology, and UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA
| | - Laurent Tesson
- Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000 Nantes, France,Nantes Université, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France,Transgenesis Rat ImmunoPhenomic Platform, F-44000 Nantes, France
| | - Jean-Marie Heslan
- Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000 Nantes, France,Nantes Université, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France,GenoCellEdit Platform, F-44000 Nantes, France
| | - Angéline Duché
- Institut Cochin, U1016 INSERM - UMR8104, CNRS - Université Paris Descartes, Genom'IC Platform, Bâtiment Gustave Roussy, F-75014 Paris, France
| | - Sébastien Jacques
- Institut Cochin, U1016 INSERM - UMR8104, CNRS - Université Paris Descartes, Genom'IC Platform, Bâtiment Gustave Roussy, F-75014 Paris, France
| | - Frédéric Ziegler
- Department of General Biochemistry, Rouen University Hospital, 76000 Rouen, France
| | - Valéry Brunel
- Department of General Biochemistry, Rouen University Hospital, 76000 Rouen, France
| | - Gilles J.P. Rautureau
- Centre de Résonance Magnétique Nucléaire à Très hauts Champs (FRE 2034, CNRS, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1), Université de Lyon, F-69100 Villeurbanne, France
| | | | - Jean-Luc do Rego
- Animal Behavioral Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, F-76183 Rouen, France
| | - Jean-Claude do Rego
- Animal Behavioral Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, F-76183 Rouen, France
| | - Carlos Afonso
- Normandie Univ, COBRA, UMR 6014 and FR 3038, Université de Rouen, INSA de Rouen, CNRS, IRCOF, F-76821, Mont-Saint-Aignan, Cedex, France
| | - Bruce Hammock
- Department of Entomology and Nematology, and UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA
| | - Anne-Marie Madec
- CarMeN Laboratory, INSERM, INRA, INSA, Université Claude Bernard Lyon 1, F-69600 Oullins, France
| | - Florence Pinet
- Institut Cochin, U1016 INSERM - UMR8104, CNRS - Université Paris Descartes, Genom'IC Platform, Bâtiment Gustave Roussy, F-75014 Paris, France
| | - Vincent Richard
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France,Department of Pharmacology, Rouen University Hospital, F-76000 Rouen, France
| | - Ignacio Anegon
- Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000 Nantes, France,Nantes Université, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France,Transgenesis Rat ImmunoPhenomic Platform, F-44000 Nantes, France
| | - Christophe Guignabert
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France,Faculté de Médecine, Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre, France
| | - Christophe Morisseau
- Department of Entomology and Nematology, and UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA
| | - Jérémy Bellien
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France; Department of Pharmacology, Rouen University Hospital, F-76000 Rouen, France.
| |
Collapse
|
6
|
Duflot T, Tu L, Leuillier M, Messaoudi H, Groussard D, Feugray G, Azhar S, Thuillet R, Bauer F, Humbert M, Richard V, Guignabert C, Bellien J. Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension? Metabolites 2021; 11:metabo11110784. [PMID: 34822442 PMCID: PMC8621392 DOI: 10.3390/metabo11110784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Accepted: 11/11/2021] [Indexed: 11/16/2022] Open
Abstract
Cardiovascular diseases (CVD) are the leading cause of premature death and disability in humans that are closely related to lipid metabolism and signaling. This study aimed to assess whether circulating lysophospholipids (LPL), lysophosphatidic acids (LPA) and monoacylglycerols (MAG) may be considered as potential therapeutic targets in CVD. For this objective, plasma levels of 22 compounds (13 LPL, 6 LPA and 3 MAG) were monitored by liquid chromatography coupled with tandem mass spectrometry (HPLC/MS2) in different rat models of CVD, i.e., angiotensin-II-induced hypertension (HTN), ischemic chronic heart failure (CHF) and sugen/hypoxia(SuHx)-induced pulmonary hypertension (PH). On one hand, there were modest changes on the monitored compounds in HTN (LPA 16:0, 18:1 and 20:4, LPC 16:1) and CHF (LPA 16:0, LPC 18:1 and LPE 16:0 and 18:0) models compared to control rats but these changes were no longer significant after multiple testing corrections. On the other hand, PH was associated with important changes in plasma LPA with a significant increase in LPA 16:0, 18:1, 18:2, 20:4 and 22:6 species. A deleterious impact of LPA was confirmed on cultured human pulmonary smooth muscle cells (PA-SMCs) with an increase in their proliferation. Finally, plasma level of LPA(16:0) was positively associated with the increase in pulmonary artery systolic pressure in patients with cardiac dysfunction. This study demonstrates that circulating LPA may contribute to the pathophysiology of PH. Additional experiments are needed to assess whether the modulation of LPA signaling in PH may be of interest.
Collapse
Affiliation(s)
- Thomas Duflot
- UNIROUEN, INSERM U1096, CHU Rouen, Department of Pharmacology, Normandie University, F-76000 Rouen, France; (V.R.); (J.B.)
- Correspondence: ; Tel.: +33-2-32-88-84-91
| | - Ly Tu
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France; (L.T.); (R.T.); (M.H.); (C.G.)
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, F-92290 Châtenay-Malabry, France
| | - Matthieu Leuillier
- UNIROUEN, INSERM U1096, Normandie University, F-76000 Rouen, France; (M.L.); (H.M.); (D.G.); (S.A.)
| | - Hind Messaoudi
- UNIROUEN, INSERM U1096, Normandie University, F-76000 Rouen, France; (M.L.); (H.M.); (D.G.); (S.A.)
| | - Déborah Groussard
- UNIROUEN, INSERM U1096, Normandie University, F-76000 Rouen, France; (M.L.); (H.M.); (D.G.); (S.A.)
| | - Guillaume Feugray
- UNIROUEN, INSERM U1096, CHU Rouen, Department of General Biochemistry, Normandie University, F-76000 Rouen, France;
| | - Saïda Azhar
- UNIROUEN, INSERM U1096, Normandie University, F-76000 Rouen, France; (M.L.); (H.M.); (D.G.); (S.A.)
| | - Raphaël Thuillet
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France; (L.T.); (R.T.); (M.H.); (C.G.)
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, F-92290 Châtenay-Malabry, France
| | - Fabrice Bauer
- UNIROUEN, INSERM U1096, CHU Rouen, Department of Cardiology, Normandie University, F-76000 Rouen, France;
| | - Marc Humbert
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France; (L.T.); (R.T.); (M.H.); (C.G.)
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, F-92290 Châtenay-Malabry, France
| | - Vincent Richard
- UNIROUEN, INSERM U1096, CHU Rouen, Department of Pharmacology, Normandie University, F-76000 Rouen, France; (V.R.); (J.B.)
| | - Christophe Guignabert
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France; (L.T.); (R.T.); (M.H.); (C.G.)
- School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, F-92290 Châtenay-Malabry, France
| | - Jérémy Bellien
- UNIROUEN, INSERM U1096, CHU Rouen, Department of Pharmacology, Normandie University, F-76000 Rouen, France; (V.R.); (J.B.)
| |
Collapse
|
7
|
Groussard D, Nezam D, Hamzaoui M, Dumenil A, Renet S, Richard V, Bellien J, Guerrot D. Endothelial deficiency in Pkd1 impairs the development of arterio-venous fistula. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2020.03.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Leuillier M, Groussard D, Lachaux M, Hamzaoui M, Henry J, Nicol L, Dumesnil A, Mulder P, Richard V, Bellien J. Effects of pharmacological inhibition of the hydrolase activity of soluble epoxide hydrolase in a murine model of pulmonary hypertension associated or not with cardiac insufficiency. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|